• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

PDL BioPharma

NASDAQ:PDLI

$6.48 -$0.01 (-0.15%)

REAL-TIME: Last trade at

Making Retirement Work Without a Huge Nest Egg

Earnings Beat at PDL BioPharma - Analyst Blog

Earnings Beat at PDL BioPharma

PDL BioPharma's CEO Discusses Q1 2012 Results - Earnings Call Transcript

PDL BioPharma reports Q1 EPS 30c, consensus 26c

PDL BioPharma Announces First Quarter 2012 Financial Results

Whisper Number Impact: Earnings Preview For Cardinal Health, Cigna, PDL BioPharma

PDL BioPharma to Announce First Quarter 2012 Financial Results on May 3, 2012

PDL BioPharma to Announce First Quarter 2012 Financial Results on May 3, 2012

PDL BioPharma Appoints Bruce Tomlinson as Chief Financial Officer

PDL BioPharma appoints Bruce Tomlinson as CFO

PDL BioPharma (PDLI) Adds Bruce Tomlinson as CFO

PDL BioPharma Appoints Bruce Tomlinson as Chief Financial Officer

10 High-Yielding Income Dividend Stocks

PDL BioPharma to Hold Annual Meeting of Stockholders on June 5, 2012

PDL BioPharma to Hold Annual Meeting of Stockholders on June 5, 2012

7 Reasons To Pick Up This Unusual 9% Yielder

PDL BioPharma Completes Regular Quarterly Dividend Payment

PDL BioPharma Completes Regular Quarterly Dividend Payment

PDL BioPharma Provides First Quarter 2012 Royalty Revenue Guidance of $77 Million

PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes

PDL BioPharma Q4 EPS In Line - Analyst Blog

PDL BioPharma Q4 EPS In Line

PDL BioPharma's CEO Discusses Q4 2011 Results - Earnings Call Transcript

PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results

PDL BioPharma to Present at Upcoming Conferences

PDL BioPharma to Present at the 14th Annual BIO CEO & Investor Conference

PDL BioPharma Announces Exchange of Its 2.875% Convertible Senior Notes due February 15, 2015

PDL BioPharma Announces Exchange of Its 2.875% Convertible Senior Notes due February 15, 2015

PDL BioPharma, Inc. (PDLI) Declares $0.15 Quarterly Dividend; 9.4% Yield

PDL BioPharma Announces 2012 Regular Quarterly Dividends

PDL BioPharma's CEO Presents at 30th Annual JP Morgan Healthcare Conference (Transcript)

PDL BioPharma sees Queen patents expiring 2013-14, royalties into 2016

PDL BioPharma affirms view of 2011 revenue $361M vs. consensus $369.95M

PDL BioPharma Announces Settlement and Final Results of its Exchange Offer

PDL BioPharma Announces Settlement and Final Results of its Exchange Offer

PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer

PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer

10 High Margin Healthcare Dividend Shares

JP Morgan's biotechnology analyst holds a conference call

See More Articles...